Shahneen Sandhu
YOU?
Author Swipe
View article: Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial Open
Inhibition of poly(ADP-ribose) polymerase (PARP) after relapse on hormone therapy is well established for patients with prostate cancer with homologous recombination repair (HRR) gene alterations, but resistance often develops. We hypothes…
View article: Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells
Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells Open
Replying to GCC Koh et al., Nature Genetics ( www.nature.com/articles/s41588-023-01602-9 ) and the comments by Simon Boulton in Nature Genetics ( www.nature.com/articles/s41588-023-01611-8 ). The drug CX-5461 [Pidnarulex] is an inhibitor o…
View article: Impact of age and comorbidity on safety outcomes in phase 1 trial participants for metastatic solid malignancies
Impact of age and comorbidity on safety outcomes in phase 1 trial participants for metastatic solid malignancies Open
Age alone was not associated with safety outcomes in phase 1 clinical trials for metastatic solid malignancies. Instead, comorbidity burden and ECOG performance status were predictors of adverse events in our cohort of patients.
View article: Data from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Data from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Purpose:Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer with poor prognosis and limited treatment options. As NEPC aberrantly expresses delta-like ligand 3 (DLL3), the activity of tarlatamab, a bispecific T-c…
View article: Supplementary Figure S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Supplementary Figure S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Supplementary Figure S2. Study design.
View article: Supplementary Table S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Supplementary Table S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Supplementary Table S1. Representativeness of study participants.
View article: Supplementary Figure S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Supplementary Figure S1 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Supplementary Figure S1. Patient disposition.
View article: Supplementary Table S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Supplementary Table S2 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Supplementary Table S2. Common (≥20%) treatment-emergent adverse events.
View article: Supplementary Figure S3 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Supplementary Figure S3 from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Supplementary Figure S3. Scatter plot for treatment response as a relationship between pretreatment T cells and DLL3 expression.
View article: SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis Open
SPARC provides a standardised PSMA PET/CT analysis and reporting consensus to serve as a future reference for PSMA PET/CT reporting. Integration of common PSMA PET reporting criteria under one umbrella improves the explanation of imaging f…
View article: Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy
Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy Open
Ribosome biogenesis is a highly coordinated, multi-step process that assembles the ribosomal machinery responsible for translating mRNAs into proteins. It begins with the rate-limiting step of RNA polymerase I (Pol I) transcription of the …
View article: Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study Open
Purpose: Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer with poor prognosis and limited treatment options. As NEPC aberrantly expresses delta-like ligand 3 (DLL3), the activity of tarlatamab, a bispecific T-…
View article: Immune checkpoint inhibitor-associated myocarditis: a novel risk score
Immune checkpoint inhibitor-associated myocarditis: a novel risk score Open
Background and Aims Immune checkpoint inhibitors (ICI) are associated with life-threatening myocarditis but milder presentations are increasingly recognized. The same autoimmune process that causes ICI myocarditis can manifest concurrent g…
View article: Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma Open
PFS in (A) part I/run-in and (B) part II. A, Kaplan–Meier analysis of PFS with encorafenib plus binimetinib in naïve and pretreated patients in the FAS population. B, Kaplan–Meier analysis of PFS in the encorafenib plus binimetinib and rib…
View article: Table 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Table 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma Open
Patient disposition (FAS population, part I/run-in, and part II).
View article: Table 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Table 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma Open
BOR as per local assessment (FAS population, part I/run-in, and part II).
View article: Supplementary Data 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Supplementary Data 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma Open
Longitudinal Genomic Analysis to Fine-Tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients With BRAF V600-Mutant Metastatic Melanoma
View article: Data from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Data from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma Open
Purpose:LOGIC 2 (NCT02159066), a multicenter, open-label, two-part, phase II study, assessed encorafenib plus binimetinib combined with a third targeted agent after tumor progression on encorafenib plus binimetinib in patients with locally…
View article: Figure 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Figure 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma Open
LOGIC 2 study design. A multicenter, open-label, two-part, phase II study to assess the efficacy and safety of encorafenib plus binimetinib (part I) followed by encorafenib plus binimetinib combined with a third targeted agent after tumor …
View article: Table 3 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Table 3 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma Open
Change in ctDNA BRAFV600E: BRAFi/MEKi naïve vs. pretreated.
View article: Table 4 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Table 4 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma Open
Overall summary of deaths and AEs (safety set, part I/run-in, and part II).
View article: rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC
rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC Open
There is an ongoing need for efficacious, life-prolonging therapies for males with metastatic castration-resistant prostate cancer (mCRPC). mCRPC that progresses after treatment with androgen receptor pathway inhibitors (ARPIs) may still b…
View article: P-541 The psychosocial and behavioural consequences of anti-müllerian hormone (AMH) testing on women
P-541 The psychosocial and behavioural consequences of anti-müllerian hormone (AMH) testing on women Open
Study question What are the psychosocial and behavioural consequences of anti-müllerian hormone (AMH) testing in women without a history of infertility? Summary answer AMH testing influenced emotional well-being and reproductive decision-m…
View article: Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial Open
The MAGNITUDE final analysis showed that patients with HRR+ mCRPC, including those with the approved indication of BRCA-altered mCRPC, generally continue to benefit from first-line treatment with niraparib + AAP in comparison to placebo + …
View article: Association of early PSMA upregulation with duration of response to enzalutamide with or without [177Lu]Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901)
Association of early PSMA upregulation with duration of response to enzalutamide with or without [177Lu]Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901) Open
Background Prostate-specific membrane antigen (PSMA) receptor expression alters in response to androgen receptor blockade in metastatic castrate resistant prostate cancer (mCRPC). The ENZA-p trial (ANZUP 1901) demonstrated that the additio…
View article: A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer Open
[Figure: see text].
View article: Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i> V600-Mutant Metastatic Melanoma
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i> V600-Mutant Metastatic Melanoma Open
Purpose: LOGIC 2 (NCT02159066), a multicenter, open-label, two-part, phase II study, assessed encorafenib plus binimetinib combined with a third targeted agent after tumor progression on encorafenib plus binimetinib in patients with locall…